- Allergy Therapeutics will be presenting data relating to the use of its patented adjuvant technology in novel therapeutic vaccine applications at the World Vaccine Congress in Madrid, 9-11 November 2015. Dr. Matthew Heath, Lead Medical Writer and Principle Scientist, will present data supporting the use of the depot adjuvant MCT in novel vaccine candidate formulations including malaria and influenza. The data has emerged through active collaborations led by Professor Martin Bachmann at University of Oxford and The Jenner Institute and also Dr Bassam Hallis at Public Health England.

Story provided by